How Long Does a Medical Device Literature Review Take Under EU MDR?

Medical Device Literature Review Timelines: What Really Determines How Long It Takes

As regulatory expectations continue to evolve, literature review has become a critical component of clinical evaluation under EU MDR, supporting activities such as benefit-risk assessment, post-market surveillance, and ongoing evidence generation. In this setting, “how long does a literature review take” is a common question, but in regulatory contexts, it is often the wrong one. A more meaningful question is what determines how long a literature review should take.

Timelines are not fixed but shaped by the complexity of the evaluation and the need to produce a structured, defensible evidence base. This reflects both the increasing complexity of medical devices and the heightened level of regulatory scrutiny applied to clinical evidence. As devices become more advanced and regulatory expectations more stringent, the literature review process must evolve accordingly, requiring greater depth, consistency, and transparency in how evidence is identified and evaluated.

Why Timelines Vary

In regulatory contexts, literature review timelines are inherently variable and depend on several interrelated factors.

Device complexity is one of the primary drivers. Novel or high-risk devices often require more extensive evaluation, including broader searches and more detailed appraisal of available evidence. Device risk classification further influences the depth of evaluation required. Higher-risk devices are subject to more rigorous clinical scrutiny, requiring more comprehensive literature searches and more detailed justification of evidence selection and interpretation. Lower-risk devices may involve more targeted reviews, but these must still meet defined methodological standards and maintain full traceability.

Novelty also plays a critical role. For well-established devices, literature may be abundant but requires careful filtering and prioritisation. For novel technologies, limited published data may necessitate broader search strategies, the inclusion of indirect evidence, or more extensive justification of clinical assumptions.

The purpose of the review significantly impacts its scope. A literature review conducted as part of an initial Clinical Evaluation Report may require a comprehensive, foundational assessment of available evidence, whereas post-market activities such as PMS or PMCF may focus more on identifying emerging trends, safety signals, or changes in the benefit-risk profile. The volume of available literature also plays a significant role. Large bodies of evidence require more time for screening, selection, and synthesis, while limited data may introduce additional challenges in identifying relevant sources or justifying conclusions.

Reviews conducted for Clinical Evaluation Reports, post-market surveillance, and post-market clinical follow-up each carry different expectations in terms of depth, frequency, and documentation. As a result, timelines cannot be standardised across projects, as each evaluation presents a unique combination of clinical and regulatory considerations.

Key Stages of a Medical Device Literature Review

The duration of a literature review is shaped by the structured stages required to ensure a robust and defensible process. These typically include the development of a search strategy, database searching, study screening, appraisal of evidence, weighting of data, and documentation of findings.

A well-defined literature search protocol, documenting search terms, databases, date ranges, and inclusion and exclusion criteria before the review begins, is one of the most effective ways to reduce iteration and improve consistency. Establishing the protocol upfront reduces the need for repeated refinement and minimises inconsistent screening decisions throughout the process.

Each stage requires both methodological rigour and clinical judgement. Screening decisions must be applied consistently, while appraisal and weighting require careful interpretation of study quality and relevance. Documentation must be sufficiently detailed to support transparency and reproducibility, both of which are essential requirements under EU MDR.

Importantly, these stages are not purely mechanical. Decisions made during screening, appraisal, and weighting require clinical and regulatory judgement, particularly when assessing borderline evidence or interpreting varied data sources. The need for consistent and justifiable decision-making across these stages contributes significantly to the overall time required.

Regulatory Expectations Under EU MDR

Within the EU MDR framework, literature review is not a standalone exercise but a key component of continuous clinical evaluation. Regulatory frameworks place increasing emphasis on traceability, requiring clear documentation of how evidence has been identified, selected, and interpreted.

Literature review must support audit readiness, enabling manufacturers to demonstrate the link between available evidence and clinical conclusions. This includes maintaining structured workflows, consistent methodology, and clear justification of decisions at every stage of the process.

Beyond individual reviews, regulatory expectations increasingly emphasise continuity across the evidence lifecycle. Literature review must maintain consistency across updates, revisions, and related regulatory outputs. Ensuring alignment between historical and newly generated evidence can introduce additional complexity and time requirements, particularly for manufacturers managing multiple devices or conducting regular PMS and PMCF updates.

Common Pitfalls and Their Consequences

Attempts to accelerate literature review timelines can introduce significant risks. Rushed screening may lead to the exclusion of relevant studies, while insufficient appraisal can result in over-reliance on lower-quality evidence. Poor documentation may further limit the ability to demonstrate compliance during regulatory review.

In practice, these risks often become evident during Notified Body assessment. Inconsistent screening decisions, poorly justified exclusions, or insufficient linkage between evidence and conclusions may result in requests for clarification or additional data, ultimately extending timelines far beyond the initial review phase.

From a clinical perspective, the implications may be more significant. Incomplete or inadequately appraised evidence can lead to gaps in understanding device performance, potentially delaying the identification of safety signals or affecting the reliability of benefit-risk assessments.

Improving Efficiency Without Compromising Quality

While timelines cannot be standardised, practical approaches can improve efficiency without compromising methodological rigour.

The most important is establishing a clearly defined search strategy from the outset, including well-considered keywords, inclusion and exclusion criteria, and predefined scope. This reduces the need for repeated refinement and minimises the risk of inconsistent screening decisions downstream.

Structured documentation also plays a critical role. Maintaining a clear audit trail during the review process prevents delays when preparing regulatory outputs or responding to Notified Body queries. Applying consistent appraisal and weighting criteria early in the process reduces rework and improves the overall coherence of the evaluation.

In practice, inefficiencies arise not from the volume of literature but from three consistent sources:

• Poorly defined search strategies that require repeated iteration
• Inconsistent application of inclusion criteria across reviewers
• Delayed or incomplete documentation that cannot support regulatory scrutiny

Efficiency is not achieved by reducing the number of steps, but by ensuring that each step is conducted in a structured, consistent, and well-documented manner.

What a Realistic Timeline Looks Like

Given these considerations, there is no fixed timeframe that can be universally applied to medical device literature review under EU MDR. Timelines should be defined based on the scope, complexity, and regulatory requirements of the specific evaluation.

A targeted review for a lower-risk, well-established device may be completed in days. A comprehensive review for a novel high-risk device requiring extensive evidence synthesis, including state-of-the-art analysis, equivalent device assessment, and detailed appraisal across multiple databases, may take several weeks. Post-market surveillance and PMCF literature updates typically sit between these extremes, depending on the volume of new evidence and the frequency of the update cycle.

A well-conducted literature review is not defined by speed, but by the extent to which it supports a clear, transparent, and credible evidence base aligned with EU MDR expectations.

Conclusion

A medical device literature review is a structured process that underpins clinical evaluation across the product lifecycle, not a task to be completed as quickly as possible. In regulatory environments, the focus is not on speed but on whether the process has been conducted in a way that supports sound, well-justified clinical conclusions.

Understanding what drives literature review timelines is essential for setting realistic expectations and planning regulatory activities effectively. Device complexity, regulatory scope, and the volume and nature of available evidence all influence the depth and effort required. Efficiency is achieved not by reducing steps, but by applying a structured and consistent approach throughout, from search protocol development through to final documentation.

If you are planning a literature review for a Clinical Evaluation Report, post-market surveillance update, or PMCF activity and want to understand the scope and timeline involved, Citemeds can help. Get in touch to discuss your requirements.

Frequently Asked Questions

How long does a medical device literature review take?

There is no fixed timeframe for a medical device literature review under EU MDR. Timelines depend on device complexity, risk classification, the volume of available literature, and the purpose of the review, whether it supports an initial Clinical Evaluation Report, a post-market surveillance update, or a PMCF activity. A targeted review for a lower-risk device may take days, while a comprehensive review for a novel high-risk device may take several weeks. The more meaningful question is not how long a review takes, but whether the process has been conducted with sufficient rigour to support a defensible evidence base.

What factors affect literature review timelines in regulatory settings?

The primary factors affecting literature review timelines under EU MDR include device risk classification, novelty of the technology, volume of available published evidence, scope of the evaluation, and the regulatory purpose of the review. Higher-risk devices require more comprehensive searches and more detailed appraisal. Novel technologies with limited published data may require broader search strategies and more extensive justification of clinical assumptions. Reviews conducted for CERs require a more foundational evidence assessment than periodic PMS or PMCF updates.

What are the key stages of a medical device literature review?

A medical device literature review under EU MDR typically involves six key stages: developing a clearly defined search protocol including keywords and inclusion and exclusion criteria; conducting database searches across sources such as PubMed, Embase, and Google Scholar; screening identified records against predefined criteria; critically appraising included studies for quality, relevance, and risk of bias; weighting evidence based on study design and methodological quality; and documenting findings in a structured, traceable format. Each stage requires both methodological rigour and clinical judgement.

What happens if a literature review is rushed?

Rushing a literature review introduces significant compliance and clinical risk. Rushed screening may lead to the exclusion of relevant studies, insufficient appraisal can result in over-reliance on lower-quality evidence, and poor documentation limits the ability to demonstrate compliance during regulatory review. These issues typically become apparent during Notified Body assessment, resulting in requests for clarification or additional data that extend timelines far beyond what a properly conducted review would have required.

How does device risk classification affect literature review scope?

Device risk classification directly determines the depth of literature review required under EU MDR. Higher-risk devices, Class IIb and Class III, require more comprehensive literature searches, more detailed critical appraisal, and more thorough justification of evidence selection and interpretation. Lower-risk devices may involve more targeted reviews, but these must still meet defined methodological standards. Risk classification also determines the frequency of literature review updates required as part of ongoing post-market surveillance obligations.

How does literature review differ for CER versus PMS versus PMCF?

A CER literature review requires a comprehensive, foundational assessment of all available clinical evidence, establishing the state of the art, assessing equivalent device data, and building the evidence base that supports the initial benefit-risk conclusion. Post-market surveillance literature reviews focus on identifying new evidence and emerging safety signals that could affect the ongoing benefit-risk profile. PMCF literature reviews are more targeted, focusing on specific clinical questions identified in the PMCF plan. Each has different scope, frequency, and documentation requirements under EU MDR.

What is a literature search protocol and why does it matter?

A literature search protocol is a predefined document specifying the research question, target databases, search terms, date ranges, and inclusion and exclusion criteria for a literature review. Under EU MDR, a clearly defined search protocol is essential for ensuring the review is reproducible, transparent, and defensible during regulatory assessment. Establishing the protocol before the review begins reduces iteration, minimises inconsistent screening decisions, and supports the audit trail required for Notified Body assessment.